March 31st, 2024

Here's RMR1 report #13!

I mentioned last time that we were around the peak of absolute rate of death per week, and that this means there is expected to be a lot of noise at present, with groups changing places a lot in terms of proportion surviving. That's very much still true this month, as you can see.

It's easy to cherry-pick conspicuous aspects of the current state of play, such as that the rapa-only group is level with the all-treatment group for females but with the all-control group for males, or that the group that was doing the worst early on (the no-telomerase males) has greatly recovered - but please don't be tempted to do that. Right now, the only metric that doesn't suffer from cherry-picking (or "the multiple hypothesis problem", to use the technical term) is the relative performance of all-treatments versus all-controls, which remains hearteningly substantial.

Meanwhile, we're still working hard behind the scenes to organise the health data we've been collecting. It's a really big job, so I'm not giving any promises about when we'll be able to start giving you some interim status reports, but be assured it's a high priority for us. Watch this space!